A new resource of use to senior living and communities and their residents, with tips on healthful eating and living, has been unveiled.
AHA: Lowering TGs with pemafibrate does not cut cardiovascular risk in type 2 diabetes
Nov 08, 2022
In patients with type 2 diabetes, hypertriglyceridemia and low HDL cholesterol levels, the risk for cardiovascular events was not lower with pemafibrate versus placebo.
Use of wearable devices low for those with cardiovascular disease risk
Jun 09, 2023
Older age, lower educational attainment and lower household income were independently associated with lower use of wearable devices in US adults at risk for CVD when adjusting for other sociodemographic...
Aortic valve replacement up in patients with Alzheimer’s disease
Sep 17, 2021
One-year outcomes were similar for patients with or without Alzheimer’s disease and related dementias.
Low HDL-C linked to coronary heart disease risk in white adults
Nov 22, 2022
High HDL-C is not protective against coronary heart disease in either white or Black adults.
OTC medications linked to cognitive impairment — again
By
Lois A. Bowers
Apr 18, 2016
Another study serves as a reminder that over-the-counter medications sold to treat colds, sleep issues, heartburn, allergies or diarrhea may come with a side effect: cognitive impairment.
Higher resting heart rate tied to dementia risk in older adults
Dec 15, 2021
An elevated resting heart rate also was associated with accelerated cognitive decline.
MIND diet scores well in ranking
By
Lois A. Bowers
Jan 11, 2016
“U.S. News & World Report” has ranked the MIND diet, said to lower the risk of Alzheimer’s disease, as the easiest diet to follow and the second best overall diet (tying in both categories)...
Fresh, delivered produce tied to improvements in CVD risk factors
Mar 22, 2024
Significant improvements were seen for produce consumption, physical activity, non-high-density lipoprotein cholesterol and HbA1c.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.